- Home
- NERV vs NXPL Comparison
NERV vs NXPL Comparison
Compare NERV & NXPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NERV
- NXPL
- Stock Information
- Founded
- NERV 2007
- NXPL 1997
- Country
- NERV United States
- NXPL United States
- Employees
- NERV N/A
- NXPL N/A
- Industry
- NERV Biotechnology: Pharmaceutical Preparations
- NXPL Telecommunications Equipment
- Sector
- NERV Health Care
- NXPL Telecommunications
- Exchange
- NERV Nasdaq
- NXPL Nasdaq
- Market Cap
- NERV 12.4M
- NXPL 13.8M
- IPO Year
- NERV 2014
- NXPL N/A
- Fundamental
- Price
- NERV $1.57
- NXPL $0.56
- Analyst Decision
- NERV Hold
- NXPL
- Analyst Count
- NERV 1
- NXPL 0
- Target Price
- NERV $5.00
- NXPL N/A
- AVG Volume (30 Days)
- NERV 5.9K
- NXPL 126.5K
- Earning Date
- NERV 05-13-2025
- NXPL 05-15-2025
- Dividend Yield
- NERV N/A
- NXPL N/A
- EPS Growth
- NERV N/A
- NXPL N/A
- EPS
- NERV 0.82
- NXPL N/A
- Revenue
- NERV N/A
- NXPL $65,483,000.00
- Revenue This Year
- NERV N/A
- NXPL N/A
- Revenue Next Year
- NERV N/A
- NXPL N/A
- P/E Ratio
- NERV $1.95
- NXPL N/A
- Revenue Growth
- NERV N/A
- NXPL 73.44
- 52 Week Low
- NERV $1.15
- NXPL $0.43
- 52 Week High
- NERV $3.69
- NXPL $2.30
- Technical
- Relative Strength Index (RSI)
- NERV 40.93
- NXPL 46.74
- Support Level
- NERV $1.58
- NXPL $0.50
- Resistance Level
- NERV $1.74
- NXPL $0.60
- Average True Range (ATR)
- NERV 0.06
- NXPL 0.05
- MACD
- NERV -0.01
- NXPL 0.02
- Stochastic Oscillator
- NERV 0.00
- NXPL 44.32
About NERV Minerva Neurosciences Inc
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.
About NXPL NextPlat Corp
NextPlat Corp is an e-commerce and healthcare company. Its e-commerce venues form an effective network serving thousands of consumers, enterprises, and governments. Its healthcare business is focused on improving the lives of patients with complex chronic diseases through patient and provider engagement and their partnerships with payors, pharmaceutical manufacturers, and distributors, offering a broad range of solutions to address the dispensing, delivery, dosing, and reimbursement of clinically intensive, high-cost drugs. The company operates in two segments: e-Commerce Operations involves acquiring and leasing an e-commerce platform; and Healthcare Operations provides TPA, data management, COVID-19 related diagnostics and vaccinations, prescription pharmaceuticals, and Others.